Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B

Chinese Medical Journal

Volumn 125, Issue 8, 2012, Pages 1434-1438

  Gu, Xi Bing ^a   Yang, Xiao Juan ^a   Hua, Zhong ^a   Lu, Zhong Hua ^a   Zhang, Bo ^a   Zhu, Yin Fang ^a   Wu, Hang Yuan ^a   Jiang, Yi Ming ^a   Chen, Hao Kun ^a   Pei, Hao ^a  

^a Wuxi Hospital for Infectious Diseases   (China)

Author keywords

Chronic hepatitis B; Cytotoxic T lymphocytes; Oxymatrine; Programmed death receptor 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; HEPATITIS B (E) ANTIBODY; HEPATITIS B (E) ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HLA A2 ANTIGEN; OXYMATRINE; PROGRAMMED DEATH 1 RECEPTOR; SILIBININ; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ALKALOIDS; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; QUINOLIZINES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84860432525     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.08.014     Document Type: Article

References (22)

1. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280.
2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
3. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117-1124.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Gu XB, Yang XJ, Wang D, Hua Z, Xu YQ, Lu ZH. Relationship between serum HBV DNA level and HBV-specific, nonspecific cytotoxic T lymphocytes and natural killer cells in patients with chronic hepatitis B. Chin Med J 2009; 122: 2129-2132.
6. Wang X, Dong XY, Zhu CA. Effects of kurarinol on peripheral blood T lymphocyte subgroups of CHB. Clin Collect 2001; 16: 841.
7. Gu XB, Yang XJ, Wang D, Zhu YF, Ding H, Zhang B, et al. Study on effect of kurarinol specific and nonspecific cellular immunity of CHB patients. Chin J Exp Clin Virol (Chin) 2009; 23: 288-291.
8. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B. Chin J Hepatol (Chin) 2011; 32: 405-415.
9. Chen Y, Li LJ. Advances in research of cell immune responses of specific cytotoxic T lymphocytes in hepatitis B virus infection. Foreign Med Sci Epidemiol Lemol (Chin) 2004; 31: 27-30.
10. He SH, Zhang JW, Chen Q, Qin ZB. Observation on therapeutic effects of kurarinol in treating 80 cases of CHB patients. Sichuan Med (Chin) 2005; 26: 1090.
11. Dong YH, Xi HL, Tian F, Kang AJ, Zhang NL, Yu M, et al. Effects of kurarinol on serum Th1 and Th2 cell factor level of HBsAg transgenic mice. Chin J Exp Clin Virol (Chin) 2004; 18: 277-280.
12. Zhou GY. Principles of immunology. Shanghai: Shanghai Sci Tech Literature Publishing House; 2000: 32-179.
13. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 1655-1665.
14. Flynn K, Mullbacher A. The generation of memory antigen-specific cytotoxic T cell responses by CD28/CD80 interactions in the absence of antigen. Eur J Immuol 1997; 27: 456-462.
15. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-347.
16. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
17. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109: 4671-4678.
18. + T-cells associated with reversible immune dysfunction. J Virol 2007; 81: 9249-9258.
19. Boni C, Fisicaro P, Valdatta C, Amadei B, Divincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225.
20. + T-cells during chronic viral infection. Nature 2006; 439: 682-687.
21. + T lymphocyte surface programmed death receptor-1 expression of CHB patients. Chin J Hepatol (Chin) 2008; 16: 706-707.
22. Evans A, Riva A, Cooksley H, Phinps S, Purank S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759-769.